JP2015013863A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015013863A5 JP2015013863A5 JP2014156852A JP2014156852A JP2015013863A5 JP 2015013863 A5 JP2015013863 A5 JP 2015013863A5 JP 2014156852 A JP2014156852 A JP 2014156852A JP 2014156852 A JP2014156852 A JP 2014156852A JP 2015013863 A5 JP2015013863 A5 JP 2015013863A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic
- ophthalmic composition
- composition according
- brimonidine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 29
- 229960003679 brimonidine Drugs 0.000 claims 12
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 11
- 239000007943 implant Substances 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 10
- 229920000642 polymer Polymers 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 229920002988 biodegradable polymer Polymers 0.000 claims 5
- 239000004621 biodegradable polymer Substances 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 210000002159 anterior chamber Anatomy 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000012377 drug delivery Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 230000004112 neuroprotection Effects 0.000 claims 2
- 239000004633 polyglycolic acid Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 230000004406 elevated intraocular pressure Effects 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- -1 poly (phosphate ester Chemical class 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 230000004304 visual acuity Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67977105P | 2005-05-10 | 2005-05-10 | |
| US60/679,771 | 2005-05-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011209152A Division JP2012046530A (ja) | 2005-05-10 | 2011-09-26 | 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015013863A JP2015013863A (ja) | 2015-01-22 |
| JP2015013863A5 true JP2015013863A5 (https=) | 2015-03-12 |
Family
ID=37397258
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511301A Pending JP2008540552A (ja) | 2005-05-10 | 2006-05-09 | 増大した前部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療 |
| JP2011209152A Pending JP2012046530A (ja) | 2005-05-10 | 2011-09-26 | 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療 |
| JP2014156852A Pending JP2015013863A (ja) | 2005-05-10 | 2014-07-31 | 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511301A Pending JP2008540552A (ja) | 2005-05-10 | 2006-05-09 | 増大した前部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療 |
| JP2011209152A Pending JP2012046530A (ja) | 2005-05-10 | 2011-09-26 | 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7931909B2 (https=) |
| EP (2) | EP1879553B1 (https=) |
| JP (3) | JP2008540552A (https=) |
| AU (1) | AU2006244083A1 (https=) |
| BR (1) | BRPI0608978A2 (https=) |
| CA (1) | CA2603069C (https=) |
| ES (1) | ES2798259T3 (https=) |
| WO (1) | WO2006122165A2 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| JP4778053B2 (ja) | 2005-07-14 | 2011-09-21 | リセラ，インコーポレイテッド | 局所的脂肪組織処置のための徐放性増強脂肪分解処方物 |
| EP1924292A2 (en) * | 2005-09-16 | 2008-05-28 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
| US20070203144A1 (en) * | 2006-01-17 | 2007-08-30 | Allergan, Inc. | Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals |
| PL2077830T3 (pl) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| WO2008157614A2 (en) * | 2007-06-21 | 2008-12-24 | Yale University | Sustained intraocular delivery of drugs from biodegradable polymeric microparticles |
| US20090081277A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| JP5591226B2 (ja) | 2008-05-12 | 2014-09-17 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | 眼内薬物送達装置および関連する方法 |
| US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US8034813B2 (en) | 2008-11-18 | 2011-10-11 | Bausch & Lomb Incorporated | Polymorphs of brimonidine pamoate |
| WO2010093945A2 (en) | 2009-02-13 | 2010-08-19 | Glaukos Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| US8633181B2 (en) | 2009-04-09 | 2014-01-21 | Rutgers, The State University Of New Jersey | Treatment of cutaneous hemangioma |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| CA3186189A1 (en) | 2009-05-18 | 2010-11-25 | Dose Medical Corporation | Drug eluting ocular implant |
| WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| PH12012500928A1 (en) | 2009-11-09 | 2012-11-26 | Allergan Inc | Compositions and methods for stimulating hair growth |
| US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
| US8492557B2 (en) | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |
| US9370444B2 (en) | 2010-10-12 | 2016-06-21 | Emmett T. Cunningham, JR. | Subconjunctival conformer device and uses thereof |
| US8915877B2 (en) | 2010-10-12 | 2014-12-23 | Emmett T. Cunningham, JR. | Glaucoma drainage device and uses thereof |
| US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
| US9597531B2 (en) | 2010-11-24 | 2017-03-21 | Neothetics, Inc. | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
| ES2552100T3 (es) | 2010-12-16 | 2015-11-25 | Allergan, Inc. | Nuevos derivados de 1,2-bis-sulfonamida como moduladores de receptores de quimiocinas |
| CA2822039C (en) | 2010-12-16 | 2019-05-28 | Allergan, Inc. | Sulfur derivatives as chemokine receptor modulators |
| US8349005B2 (en) | 2011-01-03 | 2013-01-08 | Masatoshi Murata | Method for burying implant to choroid |
| EP2673263A1 (en) | 2011-02-11 | 2013-12-18 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators |
| US8653299B2 (en) | 2011-03-17 | 2014-02-18 | Allergan, Inc. | Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| EP2782569A1 (en) | 2011-11-21 | 2014-10-01 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases |
| US20130190324A1 (en) * | 2011-12-23 | 2013-07-25 | The Regents Of The University Of Colorado, A Body Corporate | Topical ocular drug delivery |
| WO2013116186A1 (en) | 2012-01-30 | 2013-08-08 | Allergan, Inc. | Brimonidine for treating visual disorders mediated by central visual projections from the eye |
| US8815915B2 (en) | 2012-03-01 | 2014-08-26 | Allergan, Inc. | Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators |
| BR112015006929A2 (pt) | 2012-09-27 | 2017-07-04 | Allergan Inc | sistemas de distribuição de droga biodegradável para liberação sustentada de proteínas |
| EP2945686B1 (en) | 2013-01-15 | 2024-11-20 | The Regents of The University of Colorado, A Body Corporate | Lacrimal system drug delivery device |
| CN109602691A (zh) | 2013-02-15 | 2019-04-12 | 阿勒根公司 | 持续药物递送植入物 |
| WO2014159657A1 (en) | 2013-03-12 | 2014-10-02 | Allergan, Inc. | Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| WO2014152144A1 (en) | 2013-03-15 | 2014-09-25 | Acadia Pharmaceuticals Inc. | Muscarinic agonists |
| US20150152080A1 (en) | 2013-12-02 | 2015-06-04 | Allergan, Inc. | Benzothiophene sulfonamides derivatives as chemokine receptor modulators |
| KR101587483B1 (ko) * | 2014-03-28 | 2016-01-21 | 동아대학교 산학협력단 | 미토콘드리아성 복합체 ⅰ 저해제를 유효성분으로 함유하는 증식성 유리체망막병증의 예방 또는 치료용 약학적 조성물 |
| EP3677229A1 (en) | 2014-05-29 | 2020-07-08 | Glaukos Corporation | Implants with controlled drug delivery features |
| HRP20220522T1 (hr) | 2014-08-04 | 2022-06-10 | Nuevolution A/S | Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| AU2016359288C1 (en) | 2015-11-23 | 2022-03-17 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal system for drug delivery |
| EP3442479B1 (en) | 2016-04-20 | 2026-03-04 | Glaukos Corporation | Bioresorbable ocular drug delivery device |
| EP3458030B1 (en) | 2016-05-20 | 2021-05-12 | The Regents of The University of Colorado, A Body Corporate | Lacrimal drug delivery device |
| WO2018093797A1 (en) | 2016-11-15 | 2018-05-24 | The Schepens Eye Research Institute, Inc. | Compositions and methods for the treatment of aberrant angiogenesis |
| WO2018125930A1 (en) * | 2016-12-27 | 2018-07-05 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| WO2019099560A1 (en) * | 2017-11-14 | 2019-05-23 | The Schepens Eye Research Institute, Inc. | Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
| AU2019325486A1 (en) * | 2018-08-21 | 2021-03-25 | Allergan, Inc. | The use of alpha-2-adrenergic receptor agonists for improving vision |
| GB2601922B (en) | 2019-06-27 | 2024-04-24 | Layerbio Inc | Ocular device drub delivery systems |
| MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| US11685727B2 (en) | 2019-12-20 | 2023-06-27 | Nuevolution A/S | Compounds active towards nuclear receptors |
| CA3174176A1 (en) | 2020-03-31 | 2021-10-07 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
| EP4126874A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| JP2023541372A (ja) * | 2020-08-21 | 2023-10-02 | オクロセラピー リミテッド ライアビリティ カンパニー | 神経保護方法及びその使用 |
| US20230301993A1 (en) * | 2020-08-21 | 2023-09-28 | Vyluma Inc. | Low-Dose Ophthalmic Compositions and Methods |
| EP4346720A4 (en) | 2021-05-28 | 2025-01-01 | Sight Sciences, Inc. | INTRAOCULAR DEVICES, SYSTEMS AND METHODS |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| JPS58126435U (ja) | 1982-02-19 | 1983-08-27 | オリンパス光学工業株式会社 | Ｔｔｌオ−トストロボ用絞り制御回路 |
| US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| CA2300154C (en) | 1997-08-11 | 2008-07-08 | Allergan Sales, Inc. | Sterile bioerodible implant device with improved biocompatability and method |
| US6242442B1 (en) * | 1998-12-17 | 2001-06-05 | Alcon Laboratories, Inc. | Brinzolamide and brimonidine for treating ocular conditions |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| AUPQ496500A0 (en) | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
| AU2002248284A1 (en) * | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| AU2002236495B2 (en) | 2000-11-29 | 2006-05-11 | Allergan, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| US20030114460A1 (en) * | 2001-12-14 | 2003-06-19 | Allergan Sales, Inc. | Pharmaceutical conjugates with enhanced pharmacokinetic characteristics |
| DE60327693D1 (de) | 2002-03-18 | 2009-07-02 | Novartis Ag | Topische zusammensetzung enthaltend ein cyclofructan, einen träger und einen arzneistoff |
| WO2005039567A1 (en) * | 2003-10-08 | 2005-05-06 | Allergan, Inc. | Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
-
2006
- 2006-05-02 US US11/416,929 patent/US7931909B2/en active Active
- 2006-05-09 EP EP06752463.7A patent/EP1879553B1/en active Active
- 2006-05-09 WO PCT/US2006/018019 patent/WO2006122165A2/en not_active Ceased
- 2006-05-09 AU AU2006244083A patent/AU2006244083A1/en not_active Abandoned
- 2006-05-09 ES ES06752463T patent/ES2798259T3/es active Active
- 2006-05-09 EP EP20150705.0A patent/EP3656374A1/en not_active Withdrawn
- 2006-05-09 BR BRPI0608978-0A patent/BRPI0608978A2/pt not_active IP Right Cessation
- 2006-05-09 JP JP2008511301A patent/JP2008540552A/ja active Pending
- 2006-05-09 CA CA2603069A patent/CA2603069C/en active Active
-
2007
- 2007-12-03 US US11/949,751 patent/US20080112923A1/en not_active Abandoned
- 2007-12-03 US US11/949,750 patent/US20080112922A1/en not_active Abandoned
-
2011
- 2011-09-26 JP JP2011209152A patent/JP2012046530A/ja active Pending
-
2014
- 2014-07-31 JP JP2014156852A patent/JP2015013863A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015013863A5 (https=) | ||
| Allyn et al. | Considerations for polymers used in ocular drug delivery | |
| JP6570513B2 (ja) | 持続的眼内放出のためのマイクロスフェア薬剤送達システム | |
| US20240082150A1 (en) | Ocular compositions | |
| TWI354558B (en) | Steroid-containing sustained release intraocular i | |
| JP5586637B2 (ja) | 生分解性活性薬剤微小球の製造方法 | |
| JP6675298B2 (ja) | プロスタミド含有眼内インプラント | |
| BRPI0708622A2 (pt) | terapia ocular usando agentes que ativam a sirtuina | |
| KR20070083901A (ko) | 편리하게 이식가능한 서방형 약물 조성물 | |
| JP2007535367A (ja) | エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法 | |
| AU2016231616A1 (en) | Intraocular sustained release drug delivery systems and methods for treating ocular conditions | |
| JP2013035874A (ja) | α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント | |
| JP2007535564A (ja) | 抗興奮毒性剤持続放出眼内インプラントおよび関連方法 | |
| US11382862B2 (en) | Gel for treating periocular and/or orbital pathologies and conditions | |
| AU2010242939A1 (en) | Intraocular bioactive agent delivery compositon including a molecular partitioning system | |
| CN116133663B (zh) | 具有高前列腺酰胺负载量的眼内植入物 | |
| WO2014066653A1 (en) | Ketorolac-containing sustained release intraocular drug delivery systems | |
| CA3183343A1 (en) | Biodegradable compositions and implants | |
| JPWO2015133580A1 (ja) | 注入可能なポリ乳酸類含有組成物 | |
| HK40085854A (en) | Intraocular implant with high loading of a prostamide |